JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing
Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a
specialty pharmaceutical company focusing on research, development,
manufacturing, and distribution of narcotic, pain-management, and
addiction treatment pharmaceuticals, today announced that
Wilfred Chow has resigned from his
position as the Company's Chief Financial Officer. Guoan Zhang, Aoxing Pharma's Senior Vice
President for Finance, will assume the position of Chief Financial
Officer.
Wilfred Chow, commenting on his
resignation, stated: "My tenure as CFO for Aoxing Pharma has been
one of the most rewarding periods of my professional life. I am
proud to have assisted this extraordinary group of people in their
drive to bring much-needed pharmaceutical products to China. However, my own personal and
professional situations make this a good time to hand over the role
of CFO to Mr. Zhang. I will continue to assist Aoxing Pharma as an
advisor, and I look forward to continued participation in the
growth of this very special company."
Zhenjiang Yue, Aoxing Pharma's
Chief Executive Officer, commented: "We are grateful to
Wilfred Chow for his contribution to
our company through this year. We approach the end of 2015 with a
dramatically improved balance sheet, and much of the credit for our
current financial stability is due to Wilfred's dedicated efforts
on our behalf. I look forward to continuing my relationship with
Wilfred, as he serves as our advisor, and I wish him well in his
future business ventures."
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated
specialty pharmaceutical company with its operations in
China, specializing in research,
development, manufacturing and distribution of a variety of
narcotics and pain-management products. Headquartered in
Shijiazhuang City, outside
Beijing, Aoxing Pharma has the
largest and most advanced manufacturing facility in China for highly regulated narcotic medicines.
Its facility is one of the few GMP facilities licensed for the
manufacture of narcotic medicines by the China Food and Drug
Administration ("CFDA"). For more information, please visit:
www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company,
Inc.
Certain statements made in this press release are
forward-looking and are made pursuant to the safe harbor provisions
of the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties that may cause actual results to
differ materially from those set forth in these statements. All
forward-looking statements included herein are based upon
information available to the Company as of the date hereof and,
except as is expressly required by the federal securities laws, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
changed circumstances or future events or for any other reason. To
the extent that any statements made here are not historical, these
statements are essentially forward-looking. Undue reliance should
not be placed on forward-looking information. The economic,
competitive, governmental, technological and other risk factors
identified in the Company's filings with the Securities and
Exchange Commission, specifically, Item 1A, "Risk Factors," in the
Form 10-K for the year ended June 30,
2014, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aoxing-pharma-announces-resignation-of-cfo-300188102.html
SOURCE Aoxing Pharmaceutical Company, Inc.
